171 related articles for article (PubMed ID: 34644566)
21. EGFR is a potential therapeutic target for highly glycosylated and aggressive pancreatic neuroendocrine neoplasms.
Xiao Z; Xu H; Strosberg JR; Lu R; Zhu X; Deng S; Ding L; Ni Q; Warshaw AL; Yu X; Luo G
Int J Cancer; 2023 Jul; 153(1):164-172. PubMed ID: 36891979
[TBL] [Abstract][Full Text] [Related]
22. The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness.
Park H; Lee Y; Lee K; Lee H; Yoo JE; Ahn S; Park YN; Kim H
Pathol Oncol Res; 2021; 27():604600. PubMed ID: 34257565
[No Abstract] [Full Text] [Related]
23. Generation and characterization of CRISPR/Cas9-mediated MEN1 knockout BON1 cells: a human pancreatic neuroendocrine cell line.
Monazzam A; Li SC; Wargelius H; Razmara M; Bajic D; Mi J; Bergquist J; Crona J; Skogseid B
Sci Rep; 2020 Sep; 10(1):14572. PubMed ID: 32884006
[TBL] [Abstract][Full Text] [Related]
24. DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors.
Cives M; Partelli S; Palmirotta R; Lovero D; Mandriani B; Quaresmini D; Pelle' E; Andreasi V; Castelli P; Strosberg J; Zamboni G; Falconi M; Silvestris F
Sci Rep; 2019 Dec; 9(1):18614. PubMed ID: 31819132
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.
Camilli M; Papadimitriou K; Nogueira A; Incorvaia L; Galvano A; D'Antonio F; Ferri J; Santini D; Silvestris N; Russo A; Peeters M; Rolfo C
Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):471-478. PubMed ID: 29629846
[TBL] [Abstract][Full Text] [Related]
26. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
Pea A; Hruban RH; Wood LD
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis.
Wang F; Xu X; Ye Z; Qin Y; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():691557. PubMed ID: 34220718
[TBL] [Abstract][Full Text] [Related]
28. Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms.
Jiang R; Hong X; Zhao Y; Wu W
Cancer Lett; 2021 Feb; 499():39-48. PubMed ID: 33246093
[TBL] [Abstract][Full Text] [Related]
29. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
[TBL] [Abstract][Full Text] [Related]
30. Molecular Characterization and Treatment of Pancreatic Neuroendocrine Tumors.
De Jesus-Acosta AMC
Oncology (Williston Park); 2019 Dec; 33(12):. PubMed ID: 31914198
[No Abstract] [Full Text] [Related]
31. NETs: organ-related epigenetic derangements and potential clinical applications.
Cives M; Simone V; Rizzo FM; Silvestris F
Oncotarget; 2016 Aug; 7(35):57414-57429. PubMed ID: 27418145
[TBL] [Abstract][Full Text] [Related]
32. SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis.
Ren D; Sun Y; Zhang D; Li D; Liu Z; Jin X; Wu H
Cancer Lett; 2021 Oct; 519():277-288. PubMed ID: 34314754
[TBL] [Abstract][Full Text] [Related]
33. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
[TBL] [Abstract][Full Text] [Related]
34. Cross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization.
Capodanno Y; Chen Y; Schrader J; Tomosugi M; Sumi S; Yokoyama A; Hiraoka N; Ohki R
Neoplasia; 2021 Sep; 23(9):979-992. PubMed ID: 34352404
[TBL] [Abstract][Full Text] [Related]
35. Genes involved in neuroendocrine tumor biology.
Hofsli E
Pituitary; 2006; 9(3):165-78. PubMed ID: 17001466
[TBL] [Abstract][Full Text] [Related]
36. Endoplasmic Reticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations.
Klieser E; Illig R; Státtner S; Primavesi F; Jáger T; Swierczynski S; Kiesslich T; Kemmerling R; Bollmann C; Di Fazio P; Neureiter D
Anticancer Res; 2015 Nov; 35(11):6127-36. PubMed ID: 26504039
[TBL] [Abstract][Full Text] [Related]
37. Highlights of the biology of endocrine tumours of the gut and pancreas.
Rindi G; Bordi C
Endocr Relat Cancer; 2003 Dec; 10(4):427-36. PubMed ID: 14713255
[TBL] [Abstract][Full Text] [Related]
38. Progranulin Stimulates Proliferation of Mouse Pancreatic Islet Cells and Is Overexpressed in the Endocrine Pancreatic Tissue of an MEN1 Mouse Model.
Barbu A; Lejonklou MH; Skogseid B
Pancreas; 2016 Apr; 45(4):533-40. PubMed ID: 26495792
[TBL] [Abstract][Full Text] [Related]
39. Loss of YAP1 defines neuroendocrine differentiation of lung tumors.
Ito T; Matsubara D; Tanaka I; Makiya K; Tanei ZI; Kumagai Y; Shiu SJ; Nakaoka HJ; Ishikawa S; Isagawa T; Morikawa T; Shinozaki-Ushiku A; Goto Y; Nakano T; Tsuchiya T; Tsubochi H; Komura D; Aburatani H; Dobashi Y; Nakajima J; Endo S; Fukayama M; Sekido Y; Niki T; Murakami Y
Cancer Sci; 2016 Oct; 107(10):1527-1538. PubMed ID: 27418196
[TBL] [Abstract][Full Text] [Related]
40. UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors.
Finnerty BM; Moore MD; Verma A; Aronova A; Huang S; Edwards DP; Chen Z; Seandel M; Scognamiglio T; Du YN; Elemento O; Zarnegar R; Min IM; Fahey TJ
Endocr Relat Cancer; 2019 Apr; 26(4):411-423. PubMed ID: 30689542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
